Your browser doesn't support javascript.
loading
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue, Ruben T H M; Van De Voorde, Lien; Berbée, Maaike; van Elmpt, Wouter J C; Dubois, Ludwig J; Panth, Kranthi M; Peeters, Sarah G J A; Claessens, Ann; Schreurs, Wendy M J; Nap, Marius; Warmerdam, Fabiënne A R M; Erdkamp, Frans L G; Sosef, Meindert N; Lambin, Philippe.
Afiliação
  • Larue RT; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Van De Voorde L; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. lien.vandevoorde@gmail.com.
  • Berbée M; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • van Elmpt WJ; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Dubois LJ; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Panth KM; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Peeters SG; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Claessens A; Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
  • Schreurs WM; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Nap M; Department of Nuclear Medicine, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, The Netherlands.
  • Warmerdam FA; Department of Pathology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, The Netherlands.
  • Erdkamp FL; Department of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, The Netherlands.
  • Sosef MN; Department of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, The Netherlands.
  • Lambin P; Department of Surgery, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, The Netherlands.
BMC Cancer ; 16: 644, 2016 08 17.
Article em En | MEDLINE | ID: mdl-27535748
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mostardas de Fosforamida / Neoplasias Esofágicas / Adenocarcinoma / Quimiorradioterapia Adjuvante / Nitroimidazóis Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Female / Humans / Male Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mostardas de Fosforamida / Neoplasias Esofágicas / Adenocarcinoma / Quimiorradioterapia Adjuvante / Nitroimidazóis Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Female / Humans / Male Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido